Targeting the Gut Microbiota in CLD

As liver disease progresses, gut microbiota play a larger role in its pathogenesis. Gut microbiota therefore have become an important therapeutic target in the management of cirrhosis.2

icon of tablet and capsule

Lactulose and antibiotics are used as initial treatment for overt HE as well as for prevention of recurrent overt HE episodes.7

icon of probiotic

Probiotics and synbiotics have been assessed for the management of minimal HE;2,3,7 however there is no established standard of care to guide their use at this time.7

icon of capsule open spilling contents

Fecal microbiota transplantation is a novel method being explored in the management of recurrent overt HE, but its use has not yet been validated.2,3

icon of beaker and magnifying glass

Future therapies for cirrhosis may focus more on the gut-liver axis, which includes gut microbiota.3

Future Directions of Microbiota Research in Liver Disease3
Diagnosis of advanced fibrosis
Functional characterization of microbiota
Nonbacterial microbiota analysis
Sources of microbially mediated inflammation
Diet and cultural habits on microbiota composition
Prognostication using microbial composition and functionality
Precision microbial therapies
ASSIMILATION INTO CLINICAL PRACTICE >>
CLD = chronic liver disease.
HE = hepatic encephalopathy.
 
 

References

  1. Acharya C, Bajaj JS. Gut microbiota and complications of liver disease. Gastroenterol Clin North Am. 2017;46(1):155-169.
  2. Oikonomou T, Papatheodoridis GV, Samarkos M, Goulis I, Cholongitas E. Clinical impact of microbiome in patients with decompensated cirrhosis. World J Gastroenterol. 2018;24(34):3813-3820.
  3. Acharya C, Bajaj JS. Altered microbiome in patients with cirrhosis and complications. Clin Gastroenterol Hepatol. 2019;17:307-321.
  4. Bajaj JS, Heuman DM, Hylemon PB, et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol. 2014;60(5):940-947.
  5. Minemura M, Shimizu Y. Gut microbiota and liver diseases. World J Gastroenterol. 2015;21(6):1691-1702.
  6. Boursier J, Mueller O, Barret M, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63(3):764-775.
  7. Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60(2):715-735.
CLOSE
CLOSE

All personal information will be kept confidential and will not be shared with any parties other than Salix Pharmaceuticals and its designated partners. Click here to view our full Privacy Policy.

THANK YOU FOR YOUR REQUEST

Thank you for signing up to receive email updates from the Microbiome Consortium. By joining the Microbiome Consortium Professional Community, you will now automatically receive the latest resources and useful information about the gut microbiome.

We appreciate your interest in the gut microbiome and hope you find the information that you receive helpful.

  • STAY IN THE KNOW ON THE GUT MICROBIOME: SIGN UP NOW
  • references +
  • SIGN UP NOW
  • references +
Salix Pharmaceuticals logo